Related Experiment Video
Updated: Sep 25, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma
Stamatis J Karakatsanis1, Maria Bouzani2, Argyris Symeonidis3
1Third Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, Sotiria General Hospital, Athens, Greece.
For primary mediastinal large B-cell lymphoma (PMLBCL), both 3-weekly and biweekly rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) regimens show similar efficacy. Further studies are needed to confirm if dose-dense chemoimmunotherapy improves long-term outcomes.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Primary mediastinal large B-cell lymphoma (PMLBCL) is an aggressive non-Hodgkin lymphoma (NHL).
- Rituximab-containing chemoimmunotherapy (CIT) has improved PMLBCL prognosis.
- Optimal timing of CIT cycles in PMLBCL remains unclear.
Purpose of the Study:
- To compare the efficacy of 3-weekly versus biweekly R-CHOP regimens in PMLBCL patients.
- To evaluate treatment density's impact on PMLBCL outcomes.
Main Methods:
- Retrospective analysis of consecutively treated PMLBCL patients.
- Focus on treatment density and its correlation with outcomes.
Main Results:
- Both R-CHOP-21 (3-weekly) and R-CHOP-14 (biweekly) demonstrate high activity in PMLBCL.
- Low rates of early treatment failure were observed with both regimens.
- R-CHOP-14 did not show a significant improvement in freedom from progression (FFP) or overall survival (OS) compared to R-CHOP-21.
Conclusions:
- R-CHOP-14 and R-CHOP-21 appear equally effective for PMLBCL treatment.
- Prospective, randomized trials are necessary to determine if dose-dense regimens offer superior disease control and long-term results.
